Skip to main
ICLR
ICLR logo

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 29%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Icon has demonstrated robust growth with a 11% sequential increase in gross business awards, reflecting significant wins from biotech clients and ongoing advancement in partnerships with large pharmaceutical companies. The company has surpassed its financial targets related to the PRA acquisition, positioning itself favorably against funding environment uncertainties while also capitalizing on a favorable client and business mix. With the increasing demand for clinical trial services in the expanding contract research organization market, Icon is well-situated to accelerate its research capabilities.

Bears say

The financial outlook for Icon has become increasingly concerning, primarily due to revised EBITDA margin expectations that have decreased from approximately 20% to the high-19% range for both the current year and 2025. Additionally, the company faces significant downside risks that include slowed clinical trial activity stemming from pharmaceutical industry reprioritizations, uncertainties surrounding biotech funding, and inflationary pressures impacting operational costs. These factors collectively contribute to an atmosphere of uncertainty regarding Icon's future revenue growth and profitability.

ICON (ICLR) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 29% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 14 analysts, ICON (ICLR) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $205.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $205.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.